{
    "Trade/Device Name(s)": [
        "cobas HbA1c Test",
        "cobas b 101 system"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K163633",
    "Predicate Device Reference 510(k) Number(s)": [
        "K071466"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCP",
        "JJE"
    ],
    "Summary Letter Date": "June 15, 2017",
    "Summary Letter Received Date": "June 16, 2017",
    "Submission Date": "November 30, 2016",
    "Regulation Number(s)": [
        "21 CFR 864.7470",
        "21 CFR 862.2160"
    ],
    "Regulation Name(s)": [
        "Glycosylated hemoglobin assay",
        "Analyzer, chemistry (Photometric, discrete), for clinical use"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Glycated hemoglobin (HbA1c)",
        "Total hemoglobin"
    ],
    "Specimen Type(s)": [
        "Capillary whole blood",
        "Venous whole blood"
    ],
    "Specimen Container(s)": [
        "EDTA tube (K2 or K3)",
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "cobas b 101 system"
    ],
    "Method(s)/Technology(ies)": [
        "Latex agglutination inhibition immunoassay",
        "Photometric detection"
    ],
    "Methodologies": [
        "Immunoassay",
        "Spectrophotometry"
    ],
    "Submission Type(s)": [
        "Assay",
        "Analyzer",
        "Reagent",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for Roche Diagnostics cobas b 101 system and cobas HbA1c Test for quantitative determination of HbA1c in whole blood using latex agglutination inhibition immunoassay",
    "Indications for Use Summary": "Quantitatively determines glycated hemoglobin (HbA1c) in capillary or venous whole blood on the cobas b 101 instrument for monitoring long term blood glucose control in patients previously diagnosed with diabetes; not for screening, diagnosis, or neonatal use",
    "fda_folder": "Hematology"
}